MedTrace Logo

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

NCT04321161 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-03-25

No results posted yet for this study

Summary

In this study, the outcomes of relapsed AML patients receiving DLIs and Bicanorm (Sodium bicarbonate) were analyzed including T cell metabolism and immune phenotype.

Conditions

  • Acute Myeloid Leukemia, in Relapse

Interventions

DRUG

Bicanorm

Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days. sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)

Sponsors & Collaborators

  • University of Freiburg

    lead OTHER

Principal Investigators

  • Robert Zeiser, Prof. Dr. · Medical Center University of Freiburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2020-03-18
Completion
2020-03-18

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04321161 on ClinicalTrials.gov